https://egfr-signaling.com/ind....ex.php/most-cancers-
Presently, no medical processes permit a primary, continuous track of MDR. We identified circulating big extracellular vesicles (specifically microparticles (MPs)) that can be used to monitor disease burden, condition progression and growth of MDR in myeloma. These MPs differ phenotypically in the appearance of four necessary protein biomarkers a plasma-cell marker (CD138), the MDR necessary protein, P-glycoprotein (P-gp), the stem-cell marker (CD34); and phosphatidylserine (PS), a
Like
Comment
Share
